Seven Years of Follow Up of Trabecular Bone Score, Bone Mineral Density, Body Composition and Quality of Life in Adults with Growth Hormone Deficiency Treated with RhGH Replacement in a Single Center

Overview

Journal Ther Adv Endocrinol Metab

Specialty Endocrinology

Date 2016 Jun 14

PMID 27293538

Citations 9

Authors

Gonzalo Allo Miguel

Alicia Serraclara Pla

Myriam Lorena Partida Munoz

Guillermo Martinez Diaz-Guerra

Federico Hawkins

Affiliations

Soon will be listed here.

Abstract

Background: Adult growth hormone deficiency (AGHD) is characterized by impaired physical activity, diminished quality of life (QoL), weight and fat mass gain, decreased muscle mass and decreased bone mineral density (BMD). The aim of this study was to evaluate the effects of long-term treatment (7 years) with recombinant human growth hormone (rhGH) on metabolic parameters, body composition (BC), BMD, bone microarchitecture and QoL.

Patients And Methods: In this prospective study, BMD and BC were assessed by dual-energy X-ray absorptiometry (DXA). Bone microarchitecture was assessed with the trabecular bone score (TBS). The QoL-AGHDA test was used to assess QoL.

Results: A total of 18 AGHD patients (mean age, 37.39 ± 12.42) were included. Body weight and body mass index (BMI) showed a significant increase after 7 years (p = 0.03 and p = 0.001, respectively). There was a significant tendency of body fat mass (BFM) (p = 0.028) and lean body mass (LBM) (p = 0.005) to increase during the 7 years of rhGH treatment. There was a significant increase in lumbar spine (LS) BMD (p = 0.01). TBS showed a nonsignificant decrease after 7 years of treatment, with a change of -0.86% ± 1.95. QoL showed a large and significant improvement (p = 0.02).

Conclusion: Long-term rhGH treatment in AGHD patients induces a large and sustained improvement in QoL. Metabolic effects are variable with an increase in LBM as well as in BMI and BFM. There is a positive effect on BMD based on the increase in LS BMD, which stabilizes during long-term therapy and is not associated with a similar increase in bone microarchitecture.

Citing Articles

Bone Quality Indices Correlate with Growth Hormone Secretory Capacity in Women Affected by Weight Excess: A Cross-Sectional Study.

Gangitano E, Curreli M, Gandini O, Masi D, Spoltore M, Gnessi L J Clin Med. 2024; 13(17).

PMID: 39274277 PMC: 11395994. DOI: 10.3390/jcm13175064.

Skeletal fragility in pituitary disease: how can we predict fracture risk?.

Bioletto F, Berton A, Barale M, Aversa L, Sauro L, Presti M Pituitary. 2024; 27(6):789-801.

PMID: 39240510 PMC: 11631825. DOI: 10.1007/s11102-024-01447-3.

Quality of life in postmenopausal women with osteoporosis and osteopenia: associations with bone microarchitecture and nutritional status.

Mornar M, Novak A, Bozic J, Vrdoljak J, Kumric M, Vilovic T Qual Life Res. 2023; 33(2):561-572.

PMID: 37955793 DOI: 10.1007/s11136-023-03542-7.

Differences between bone health parameters in adults with acromegaly and growth hormone deficiency: A systematic review.

Freda P Best Pract Res Clin Endocrinol Metab. 2023; 37(6):101824.

PMID: 37798201 PMC: 10843107. DOI: 10.1016/j.beem.2023.101824.

Metabolic and quality of life effects of growth hormone replacement in patients with TBI and AGHD: A pilot study.

Herodes M, Le N, Anderson L, Migula D, Miranda G, Paulsen L Growth Horm IGF Res. 2023; 71:101544.

PMID: 37295336 PMC: 10527000. DOI: 10.1016/j.ghir.2023.101544.

References

Biller B, Sesmilo G, Baum H, Hayden D, Schoenfeld D, Klibanski A . Withdrawal of long-term physiological growth hormone (GH) administration: differential effects on bone density and body composition in men with adult-onset GH deficiency. J Clin Endocrinol Metab. 2000; 85(3):970-6. DOI: 10.1210/jcem.85.3.6474. View

Appelman-Dijkstra N, Claessen K, Roelfsema F, Pereira A, Biermasz N . Long-term effects of recombinant human GH replacement in adults with GH deficiency: a systematic review. Eur J Endocrinol. 2013; 169(1):R1-14. DOI: 10.1530/EJE-12-1088. View

Silva B, Boutroy S, Zhang C, McMahon D, Zhou B, Wang J . Trabecular bone score (TBS)--a novel method to evaluate bone microarchitectural texture in patients with primary hyperparathyroidism. J Clin Endocrinol Metab. 2013; 98(5):1963-70. PMC: 3644593. DOI: 10.1210/jc.2012-4255. View

van der Klaauw A, Biermasz N, Feskens E, Bos M, Smit J, Roelfsema F . The prevalence of the metabolic syndrome is increased in patients with GH deficiency, irrespective of long-term substitution with recombinant human GH. Eur J Endocrinol. 2007; 156(4):455-62. DOI: 10.1530/EJE-06-0699. View

Cabo D, Lecube A, Barrios M, Mesa J . [Long term treatment with growth hormone deficiency in adults]. Med Clin (Barc). 2011; 136(15):659-64. DOI: 10.1016/j.medcli.2010.07.030. View

Molitch M, Clemmons D, Malozowski S, Merriam G, Vance M . Evaluation and treatment of adult growth hormone deficiency: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2011; 96(6):1587-609. DOI: 10.1210/jc.2011-0179. View

Kuzma M, Kuzmova Z, Zelinkova Z, Killinger Z, Vanuga P, Lazurova I . Impact of the growth hormone replacement on bone status in growth hormone deficient adults. Growth Horm IGF Res. 2014; 24(1):22-8. DOI: 10.1016/j.ghir.2013.12.001. View

Tritos N, Biller B . Growth hormone and bone. Curr Opin Endocrinol Diabetes Obes. 2009; 16(6):415-22. DOI: 10.1097/MED.0b013e3283319e6d. View

de Boer H, Blok G, van der Veen E . Clinical aspects of growth hormone deficiency in adults. Endocr Rev. 1995; 16(1):63-86. DOI: 10.1210/edrv-16-1-63. View

10.

Bex M, Abs R, Maiter D, Beckers A, Lamberigts G, Bouillon R . The effects of growth hormone replacement therapy on bone metabolism in adult-onset growth hormone deficiency: a 2-year open randomized controlled multicenter trial. J Bone Miner Res. 2002; 17(6):1081-94. DOI: 10.1359/jbmr.2002.17.6.1081. View

11.

Littley M, Shalet S, Beardwell C, Ahmed S, Applegate G, Sutton M . Hypopituitarism following external radiotherapy for pituitary tumours in adults. Q J Med. 1989; 70(262):145-60. View

12.

Diez J, Cordido F . [Benefits and risks of growth hormone in adults with growth hormone deficiency]. Med Clin (Barc). 2014; 143(8):354-9. DOI: 10.1016/j.medcli.2013.11.026. View

13.

Holmes S, Economou G, Whitehouse R, Adams J, Shalet S . Reduced bone mineral density in patients with adult onset growth hormone deficiency. J Clin Endocrinol Metab. 1994; 78(3):669-74. DOI: 10.1210/jcem.78.3.8126140. View

14.

Kristensen E, Hallgrimsson B, Morck D, Boyd S . Microarchitecture, but not bone mechanical properties, is rescued with growth hormone treatment in a mouse model of growth hormone deficiency. Int J Endocrinol. 2012; 2012:294965. PMC: 3312192. DOI: 10.1155/2012/294965. View

15.

Appelman-Dijkstra N, Claessen K, Hamdy N, Pereira A, Biermasz N . Effects of up to 15 years of recombinant human GH (rhGH) replacement on bone metabolism in adults with growth hormone deficiency (GHD): the Leiden Cohort Study. Clin Endocrinol (Oxf). 2014; 81(5):727-35. DOI: 10.1111/cen.12493. View

16.

Elbornsson M, Gotherstrom G, Bosaeus I, Bengtsson B, Johannsson G, Svensson J . Fifteen years of GH replacement increases bone mineral density in hypopituitary patients with adult-onset GH deficiency. Eur J Endocrinol. 2012; 166(5):787-95. PMC: 3341655. DOI: 10.1530/EJE-11-1072. View

17.

Moock J, Albrecht C, Friedrich N, Volzke H, Nauck M, Koltowska-Haggstrom M . Health-related quality of life and IGF-1 in GH-deficient adult patients on GH replacement therapy: analysis of the German KIMS data and the Study of Health in Pomerania. Eur J Endocrinol. 2008; 160(1):17-24. DOI: 10.1530/EJE-08-0738. View

18.

Hazem A, Elamin M, Bancos I, Malaga G, Prutsky G, Domecq J . Body composition and quality of life in adults treated with GH therapy: a systematic review and meta-analysis. Eur J Endocrinol. 2011; 166(1):13-20. DOI: 10.1530/EJE-11-0558. View

19.

Gotherstrom G, Bengtsson B, Bosaeus I, Johannsson G, Svensson J . A 10-year, prospective study of the metabolic effects of growth hormone replacement in adults. J Clin Endocrinol Metab. 2007; 92(4):1442-5. DOI: 10.1210/jc.2006-1487. View

20.

Badia X, Lucas A, Sanmarti A, Roset M, Ulied A . One-year follow-up of quality of life in adults with untreated growth hormone deficiency. Clin Endocrinol (Oxf). 1999; 49(6):765-71. DOI: 10.1046/j.1365-2265.1998.00634.x. View